Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05242458 · ClinicalTrials.gov registry record
A Study of Ustekinumab Treatment in Children With Crohn's Disease
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 545
- Enrollment target
NCT05242458 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 545 participants.
The verdict
NCT05242458 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 545 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of ustekinumab in achieving clinical remission in pediatric participants (greater than or equal to \[\>=\] 2 to less than \[\<\] 18 years and weight \>= 40 kilograms \[kg\] at baseline).
Interventions
- DRUG Ustekinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2023-05-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05242458
The ClinicalTrials.gov registry entry for NCT05242458 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 545 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ustekinumab is the first listed.
NCT05242458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05242458 about?
NCT05242458 is a clinical study titled "A Study of Ustekinumab Treatment in Children With Crohn's Disease". The purpose of this study is to evaluate the effectiveness of ustekinumab in achieving clinical remission in pediatric participants (greater than or equal to \[\>=\] 2 to less than \[\<\] 18 years and weight \>= 40 kilograms \[kg\] at baseline).
What is the current status of trial NCT05242458?
This trial is currently completed. The enrollment target is 545 participants. The study started on 2022-03-21. Estimated completion is 2023-05-22.
What interventions are being tested in trial NCT05242458?
The interventions under investigation include: Ustekinumab (DRUG).
Who is sponsoring clinical trial NCT05242458?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.